Shattuck Labs, Inc. (NASDAQ: STTK) was founded in 2016 and is headquartered in Austin, Texas, USA. It has 45 full-time employees. It is an innovative clinical stage biotechnology company dedicated to dual-sided fusion proteins (dual-sided fusion proteins). ) Developed as a brand-new biomedical product.
Shattuck Labs, Inc. (STTK):
Shattuck was founded in 2016 with the goal of establishing a fully integrated biotechnology company that develops new therapies for the treatment of cancer and autoimmune diseases. The core of this vision is to create a company that brings together leading scientists, drug manufacturers, physicians and other professionals to challenge traditional thinking and develop transformable drugs that can improve the lives of patients.
One of Shattuck’s truly unique aspects is the novelty of the company’s proprietary Agonist Redirected Checkpoint (ARC) platform technology-combining a strong technical foundation with deep expertise to enable the company to fulfill a broader corporate mission.
So far, Shattuck’s research and discovery engine has produced more than 300 ARC compounds and achieved great results. Shattuck’s discovery work is the cornerstone of all the company’s work, and the company has invested a lot of money to understand the science behind all the company’s compounds. Thanks to the heavy investment in the Shattuck platform, the company was able to transfer the compound from the laboratory to the clinic in less than 18 months, far exceeding the industry standard timetable.
Shattuck believes that the company’s method may fundamentally change the therapeutic regulation of the immune system. Compounds derived from the company’s proprietary Agonist Redirected Checkpoint (ARC®) platform can simultaneously inhibit checkpoint molecules and activate costimulatory molecules in a single therapeutic agent.
Shattuck Lab’s main wholly-owned candidate product-SL-172154 (SIRPα-Fc-CD40L) is rationally designed to simultaneously inhibit CD47/SIRPa checkpoint interaction to restore anti-tumor immune responses and activate CD40 costimulatory receptors to enhance Immune response. Shattuck Lab is currently conducting a phase I clinical trial evaluating SL-172154 for patients with ovarian cancer, and is expected to announce preliminary data on the dose escalation portion of the trial in the second half of 2021.
Another product candidate of Shattuck Lab, SL-279252 (PD1-Fc-OX40L), was developed in cooperation with Takeda , and after reasonable design, it can simultaneously inhibit PD-1/PD-L1 interaction and activate OX40 receptors . Shattuck Lab is evaluating SL-279252 in a phase I clinical trial for advanced solid tumors and lymphomas, and hopes to announce the dose escalation part of the trial data in the second half of 2021.
Shattuck Labs, Inc. (STTK) Financing:
- On August 22, 2016, Shattuck Labs, Inc. received US$3.4 million through debt financing.
- On April 10, 2017, Shattuck Labs, Inc. obtained $7 million in funding through debt financing.
- On May 24, 2018, in Series A financing, Shattuck Labs, Inc. received US$46.6 million in investment.
- On June 15, 2020, in the B round of financing, Shattuck Labs, Inc. received a lead investment from Redmile Group and a follow-up investment of US$118 million from 8 institutions including Fidelity Management and Research Company, Hatteras Venture Partners, EcoR1 Capital, and Emerson Collective.
Shattuck Labs, Inc. (STTK) investment:
Shattuck Labs, Inc. (NASDAQ:STTK) listed on NASDAQ on 10/9/2020 IPO. The planned issue price is $14.00-$16.00, the actual issue price is US$17, 10 million shares are issued, 170 million US dollars are raised, Citigroup/ Cowen/Evercore ISI underwriting, Joint Needham & Co.